*The 3-year first-time residency attainment rate is the weighted average of the 2022-23, through 2024-25 academic years. For each year, the rate is the percent of students attaining a residency out of all graduates or expected graduates in the year who were active applicants in the NRMP match in that year or who attained a residency outside the NRMP match in that year. The 1-year first-time residency attainment rate is 95% for 2024-2025 graduates.
Mazin Al-Salihi, PhD
Associate Professor, Pathology
Dr. Mazin Al-Salihi is a Fulbright award recipient. He earned his medical degree in medicine and surgery from the University of Jordan and received a PhD in oncological sciences from the University of Utah. In 2021, Dr. Al-Salihi joined AUC as an associate professor and is the module leader for Pathology II at AUC’s UK faculty. He has been teaching and supervising medical and postgraduate students since 2005 and is a strong proponent of equality in STEMM.
Dr. Al-Salihi’s research interests concentrate on cell signalling through protein phosphorylation and ubiquitylation as well as DNA methylation and its effects on carcinogenesis. Prior to joining AUC, Dr. Al-Salihi was engaged in cell signalling research at Heinrich Heine Universität’s Institute of Molecular Medicine, and held an assistant professor position at the University of Jordan’s school of medicine teaching pathology. His research there concentrated on iRhoms and LRRK1 in liver disease, stem cell immune modulation of inflammatory bowel disease, and EGFR mutations in “never smokers” lung cancer. He also conducted research at the Medical Research Council’s Protein phosphorylation Unit on deubiquitylase modulation of TGFb and BMP signalling in carcinogenesis. His postdoctoral research covered epigenetic modulation of solid tumors using DNA methyl transferase inhibitors, immune myeloperoxidase inhibition therapy in colon carcinogenesis, elucidating the COX-2 EGFR transactivation pathway and COX-2’s role in colon cancer progression.